- All patients with metastatic colorectal cancer should undergo testing for KRAS, NRAS, and BRAF status and microsatellite instability/mismatch repair status.
- The addition of epidermal growth factor receptor inhibitors to chemotherapy in the first-line setting in patients with RAS and BRAF wild-type metastatic colorectal cancer improves survival.
- Patients with right-sided primary colon tumors have worse overall survival and derive less benefit from cetuximab (even if their tumors are KRAS wild-type) than patients with left-sided tumors.
- While great strides have been made, many patients still do not reap an overall survival benefit from currently available biologic therapy. Therefore, additional novel therapies and combination approaches are needed.